A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Holkova Beata; Zingone Adriana; Kmieciak Maciej; Bose Prithviraj; Badros Ashraf Z.; Voorhees Peter M.; Baz Rachid; Korde Neha; Lin Hui-Yi; Chen Jin-Qiu; Herrmann Michelle; Xi Liqiang; Raffeld Mark; Zhao Xiuhua; Wan Wen; Tombes Mary Beth; Shrader Ellen; Weir-Wiggins Caryn; Sankala Heidi; Hogan Kevin T.; Doyle Austin; Annunziata Christina M.; Wellons Martha; Roberts John D.; Sullivan Daniel; Landgren Ola; Grant Steven

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

【24h】

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

机译：口服MEK1 / 2抑制剂AZD6244（Selumetinib，ARRY-142886）在复发/难治性多发性骨髓瘤中的II期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: AZD6244 is a MEK1/2 inhibitor with significant preclinical activity in multiple myeloma cells. This phase II study used a two-stage Simon design to determine the AZD6244 response rate in patients with relapsed or refractory multiple myeloma.

机译：目的：AZD6244是一种MEK1 / 2抑制剂，在多发性骨髓瘤细胞中具有显着的临床前活性。这项II期研究使用了两个阶段的Simon设计来确定复发或难治性多发性骨髓瘤患者的AZD6244反应率。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2016年第5期|共9页
作者
Holkova Beata; Zingone Adriana; Kmieciak Maciej; Bose Prithviraj; Badros Ashraf Z.; Voorhees Peter M.; Baz Rachid; Korde Neha; Lin Hui-Yi; Chen Jin-Qiu; Herrmann Michelle; Xi Liqiang; Raffeld Mark; Zhao Xiuhua; Wan Wen; Tombes Mary Beth; Shrader Ellen; Weir-Wiggins Caryn; Sankala Heidi; Hogan Kevin T.; Doyle Austin; Annunziata Christina M.; Wellons Martha; Roberts John D.; Sullivan Daniel; Landgren Ola; Grant Steven;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma [J] . Holkova Beata, Zingone Adriana, Kmieciak Maciej, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第5期

机译：口服MEK1 / 2抑制剂AZD6244（Selumetinib，ARRY-142886）在复发/难治性多发性骨髓瘤中的II期试验
2. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements [J] . HayesD.N., LucasA.S., TanvetyanonT., Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第7期

机译：selumetinib（AZD6244; ARRY-142886）在碘131难治性甲状腺乳头状癌伴或不伴滤泡成分的II期疗效和药物基因组学研究
3. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements [J] . HayesD.N., LucasA.S., TanvetyanonT., Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第7期

机译：selumetinib（AZD6244; ARRY-142886）在碘131难治性甲状腺乳头状癌伴或不伴滤泡成分的II期疗效和药物基因组学研究
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. A Phase 2 Trial of AZD6244 (Selumetinib ARRY-142886) an Oral MEK1/2 Inhibitor in Relapsed/Refractory Multiple Myeloma [O] . Beata Holkova, Adriana Zingone, Maciej Kmieciak, -1

机译：口服MEK1 / 2抑制剂AZD6244（SelumetinibARRY-142886）在复发/难治性多发性骨髓瘤中的2期试验
7. Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma [O] . Federica Catalanotti, David B. Solit, Melissa P. Pulitzer, 2013

机译：BRAFV600E / K型黑色素瘤患者MEK抑制剂SELUMETINIB（AZD6244，ARRY-142886）的II期试验

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅